<DOC>
	<DOC>NCT02923466</DOC>
	<brief_summary>This is a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of intratumoral administration of VSV-IFNÎ²-NIS in patients with refractory advanced/metastatic solid tumors.</brief_summary>
	<brief_title>Trial of Intratumoral Administration of Recombinant Vesicular Stomatitis Virus in Patients With Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Vesicular Stomatitis</mesh_term>
	<criteria>Be &gt; 18 years of age on day of signing informed consent. Have a histologically confirmed diagnosis of an advanced and/or metastatic solid tumor that is relapsed and/or refractory to standard therapy, as defined as progression on at least one prior line of therapy in the relapsed/metastatic setting and no existing options are felt to provide clinical benefit. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1. Adequate hematological, liver and kidney function. Must be willing to implement contraception throughout study and for 120 days after receiving the study drug. Has been receiving any other investigational agents, chemotherapy, immunotherapy, radiotherapy or molecular targeted agents within 4 weeks of the start treatment. Has a history of a bone marrow or solid organ transplant. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the prescreening or screening visit through 120 days after the last dose of trial treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>refractory solid tumor</keyword>
</DOC>